Participation of IIb-IIIa glycoprotein in spontaneous platelet aggregation

Bulletin of Experimental Biology and Medicine
O V SirotkinaA V Mazurov

Abstract

In some patients with stable and unstable angina pectoris and in some donors without clinical manifestations of cardiovascular diseases and other pathologies, spontaneous platelet aggregation was completely suppressed by glycoprotein IIb-IIIa antagonists blocking the interaction of this glycoprotein with fibrinogen. Antibodies inhibiting binding of glycoprotein Ib with von Willebrand factor had no effect on the level and rate of spontaneous platelet aggregation. In the donor group, the level of spontaneous aggregation was almost 1.5-fold higher in persons with a certain genetic polymorphism (Leu-->Pro substitution in position 33 of glycoprotein IIIa). The level of spontaneous aggregation correlated with the amount of glycoprotein IIb-IIIa on the platelet surface (r = 0.41).

References

May 31, 1990·The New England Journal of Medicine·M D TripJ Vreeken
Apr 25, 1996·The New England Journal of Medicine·E J WeissP J Goldschmidt-Clermont
Apr 9, 1999·Arteriosclerosis, Thrombosis, and Vascular Biology·D FengG H Tofler
Mar 23, 2000·The Journal of Clinical Investigation·K V VijayanP F Bray
Mar 15, 2003·Arteriosclerosis, Thrombosis, and Vascular Biology·Martin J QuinnEdward F Plow
Jul 23, 2003·Journal of Thrombosis and Haemostasis : JTH·Z M Ruggeri

❮ Previous
Next ❯

Citations

Dec 2, 2008·Bulletin of Experimental Biology and Medicine·M B PlotnikovE A Krasnov
May 15, 2013·Bulletin of Experimental Biology and Medicine·A V MazurovM Ya Ruda

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.